Monoclonal Antibodies (MAs) Global Market Report 2024

Description

Monoclonal antibodies (MABs) are laboratory-created proteins designed to enhance the immune system's capabilities. These treatments are typically administered as IV solutions, often in specialized infusion centers. Antibodies function as vital components of the immune system by targeting and binding to antigens (foreign substances) to neutralize them.

There are several sources of monoclonal antibodies: murine, chimeric, humanized, and fully human. Murine antibodies contain two types of chains, one from a mouse and the other from a human. The prefix 'o-' in the International Nonproprietary Name (INN) identifies murine antibodies. They find applications in various fields such as anti-cancer treatments, immunology, anti-infective therapies, neuropharmacology, cardiovascular and cerebrovascular conditions. These antibodies are utilized across different sectors including hospitals, private clinics, and research institutes.

The monoclonal antibodies (MABS) market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibodies (MABS) market statistics, such as industry global market size, regional shares, competitors with a monoclonal antibodies (MABS) market share, detailed monoclonal antibodies (MABS) market segments, market trends and opportunities, and any additional data you may require to thrive in the monoclonal antibodies (MABS) industry. This monoclonal antibody (MABS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The monoclonal antibodies (mabs) market size has grown rapidly in recent years. It will grow from $234.37 billion in 2023 to $261.66 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. Historical growth in the use of monoclonal antibodies (MABs) can be linked to several factors, including the rising prevalence of chronic diseases, increased investment in research and development (R&D), a growing awareness of the benefits of MABs, and the expanding elderly population's healthcare needs.

The monoclonal antibodies (mabs) market size is expected to see rapidly grown in the next few years. It will grow to $424.24 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. Anticipated growth in the forecast period for monoclonal antibodies (MABs) is tied to several key factors, including the expansion of therapeutic applications, the rise of personalized medicine approaches, the development of biosimilars and generics, the utilization of combination therapies, increased focus on pandemic preparedness, and heightened investment in biopharmaceuticals.

The escalation of cost-efficient biosimilar monoclonal antibodies stands as a pivotal driver propelling the monoclonal antibody market's expansion. Biosimilars, designed to counter escalating healthcare costs and governmental pressures for reduced medication expenses, replicate biological drugs at a lower cost, with biosimilar monoclonal antibodies costing 20%-25% less than their original counterparts. The streamlined clinical trial processes for biosimilars contribute to their cost efficiency. India's 'Guidelines on Similar Biologics' by the Central Drugs Standard Control Organization (CSDCO) augur a significant uplift for the Indian biosimilar drug industry.

The escalating prevalence of chronic diseases emerges as a catalyst driving the monoclonal antibodies (mAbs) market. Chronic conditions, uncurable but manageable, have seen increased treatment with mAbs, particularly in managing dysregulated immune responses and inflammation. Shockingly, the World Health Organization's September 2023 data revealed that 74% of global deaths, amounting to 41 million annually, are due to noncommunicable diseases (NCDs) or chronic diseases. These staggering figures, with 86% of premature NCD-related deaths occurring in low- and middle-income countries, underscore the pivotal role of mAbs in addressing chronic ailments.

The market has witnessed numerous strategic initiatives, with top companies leveraging acquisitions, collaborations, and partnerships to expand product portfolios and global reach. In March 2022, Collaborations like Sanofi S.A.'s collaboration with Seagen Inc. to develop cancer-targeting antibody-drug conjugates (ADCs) and Boehringer Ingelheim's partnership with MabGenesis, Inc. for therapeutic monoclonal antibodies exemplify this trend. Additionally, innovative technologies like RenMice, pioneered by Biocytogen Pharmaceuticals, are revolutionizing antibody-based therapies by offering a range of fully human antibodies and T-cell receptor mice with proprietary intellectual property.

Major companies operating in the monoclonal antibodies market are introducing innovative technologies such as RenMice to gain a competitive edge in the market. RenMice offers strong assistance in the exploration of various antibody-based therapies, including fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, fully human T-cell receptors (TCRs), and TCR-mimic antibodies. For instance, in September 2023, Biocytogen Pharmaceuticals, a China-based international biotech company that drives the research and development of new drugs with innovative technologies launched RenMice series, encompassing a selection of independently created fully human antibody mice and TCR mice, all of which possess proprietary intellectual property.

The regulatory support from the U.S. Food and Drug Administration (FDA) has significantly contributed to market growth, especially in the rare disease treatment segment. Accelerated approvals granted to drugs like avelumab (BAVENCIO) for metastatic Merkel cell carcinoma (MCC) and TECENTRIQ (atezolizumab) for locally-advanced or metastatic urothelial carcinoma (MUC) underscore the FDA's pivotal role in advancing monoclonal antibody therapeutics, fostering market expansion, and addressing critical medical needs.

Major companies operating in the monoclonal antibodies (MABS) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Mylan N.V., Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc

North America was the largest region in the monoclonal antibodies (MAbS) market in 2023. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the monoclonal antibodies (MABS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The monoclonal antibodies (MABS) market consists of sales of rituximab, cetuximab, and trastuzumab. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Monoclonal Antibodies (MAs) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on monoclonal antibodies (mas) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for monoclonal antibodies (mas)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The monoclonal antibodies (mas) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Source: Murine; Chimeric; Humanized; Human
2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAs); Neuropharmacological; Cardiovascular And Cerebrovascular; Other Applications
3) By End Users: Hospitals; Private Clinics; Research Institute
Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Amgen Inc.; Novartis International AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13244

1. Executive Summary

2. Monoclonal Antibodies (MAs) Market Characteristics

3. Monoclonal Antibodies (MAs) Market Trends And Strategies

4. Monoclonal Antibodies (MAs) Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Monoclonal Antibodies (MAs) Market Size and Growth

5.1. Global Monoclonal Antibodies (MAs) Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Monoclonal Antibodies (MAs) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Monoclonal Antibodies (MAs) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Monoclonal Antibodies (MAs) Market Segmentation

6.1. Global Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Murine
Chimeric
Humanized
Human
6.2. Global Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Anti-Cancer
Immunological
Anti-Infective Monoclonal Antibodies (MAs)
Neuropharmacological
Cardiovascular And Cerebrovascular
Other Applications
6.3. Global Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Private Clinics
Research Institute

7. Monoclonal Antibodies (MAs) Market Regional And Country Analysis

7.1. Global Monoclonal Antibodies (MAs) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Monoclonal Antibodies (MAs) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Monoclonal Antibodies (MAs) Market

8.1. Asia-Pacific Monoclonal Antibodies (MAs) Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Monoclonal Antibodies (MAs) Market

9.1. China Monoclonal Antibodies (MAs) Market Overview
9.2. China Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Monoclonal Antibodies (MAs) Market

10.1. India Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Monoclonal Antibodies (MAs) Market

11.1. Japan Monoclonal Antibodies (MAs) Market Overview
11.2. Japan Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Monoclonal Antibodies (MAs) Market

12.1. Australia Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Monoclonal Antibodies (MAs) Market

13.1. Indonesia Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Monoclonal Antibodies (MAs) Market

14.1. South Korea Monoclonal Antibodies (MAs) Market Overview
14.2. South Korea Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Monoclonal Antibodies (MAs) Market

15.1. Western Europe Monoclonal Antibodies (MAs) Market Overview
15.2. Western Europe Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Monoclonal Antibodies (MAs) Market

16.1. UK Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Monoclonal Antibodies (MAs) Market

17.1. Germany Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Monoclonal Antibodies (MAs) Market

18.1. France Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Monoclonal Antibodies (MAs) Market

19.1. Italy Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Monoclonal Antibodies (MAs) Market

20.1. Spain Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Monoclonal Antibodies (MAs) Market

21.1. Eastern Europe Monoclonal Antibodies (MAs) Market Overview
21.2. Eastern Europe Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Monoclonal Antibodies (MAs) Market

22.1. Russia Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Monoclonal Antibodies (MAs) Market

23.1. North America Monoclonal Antibodies (MAs) Market Overview
23.2. North America Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Monoclonal Antibodies (MAs) Market

24.1. USA Monoclonal Antibodies (MAs) Market Overview
24.2. USA Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Monoclonal Antibodies (MAs) Market

25.1. Canada Monoclonal Antibodies (MAs) Market Overview
25.2. Canada Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Monoclonal Antibodies (MAs) Market

26.1. South America Monoclonal Antibodies (MAs) Market Overview
26.2. South America Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Monoclonal Antibodies (MAs) Market

27.1. Brazil Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Monoclonal Antibodies (MAs) Market

28.1. Middle East Monoclonal Antibodies (MAs) Market Overview
28.2. Middle East Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Monoclonal Antibodies (MAs) Market

29.1. Africa Monoclonal Antibodies (MAs) Market Overview
29.2. Africa Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Monoclonal Antibodies (MAs) Market Competitive Landscape And Company Profiles

30.1. Monoclonal Antibodies (MAs) Market Competitive Landscape
30.2. Monoclonal Antibodies (MAs) Market Company Profiles
- 30.2.1. Johnson & Johnson
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck & Co. Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AbbVie Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Amgen Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis International AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Monoclonal Antibodies (MAs) Market Competitive Benchmarking

32. Global Monoclonal Antibodies (MAs) Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAs) Market

34. Monoclonal Antibodies (MAs) Market Future Outlook and Potential Analysis

34.1 Monoclonal Antibodies (MAs) Market In 2028 - Countries Offering Most New Opportunities
34.2 Monoclonal Antibodies (MAs) Market In 2028 - Segments Offering Most New Opportunities
34.3 Monoclonal Antibodies (MAs) Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer